ACT Genomics and mProbe Announces Strategic Integration of Proteomics to Elevate Precision Medicine in Asia

Taipei, Taiwan – ACT GenomicsCo. Limited, Asia’s foremost provider of next-generationsequencing (NGS) precision oncology, is proud toannounce a new milestone in its mission to improve cancer patient care: theexclusive integration of OncoOmicsDX, an innovative proteomics clinical servicedeveloped by mProbe Inc. in Taiwan, Hong Kong, Macau, Singapore, Thailand,Malaysia, Indonesia, Vietnam, and the Philippines.

This collaboration marks amajor advancement in integrating genomics and proteomics—alsoknown as proteogenomics—to enhancemolecular insights into cancer biology. By combining NGS-based genomicprofiling with proteomics-driven biomarker discovery, this approach provides amore comprehensive understanding of tumor biology, uncovering criticalmechanisms of disease progression and treatment response.

With these enhanced molecularinsights, physicians can make more precise and personalized treatmentdecisions, optimizing therapy selection based on a patient’s unique molecularprofile. This proteogenomics approach strengthens the foundation of precisiononcology, helping clinicians to identify targeted and effective treatmentstrategies for cancer patients across the region.

“Weare excited to partner with mProbe Inc. to deliver a new dimension in precisiononcology,” said Dr. Hua ChienChen, CEO of ACT Genomics. “With OncoOmicsDX, healthcare providers gain aholistic view of cancer biology, allowing them to make data-driven decisionsthat can significantly improve patient cares.”

OncoOmicsDX harnessesadvanced mass spectrometry and AI-driven analytics to identify proteinbiomarkers linked to cancer progression and treatment response. This additionallayer of information complements genomic data, creating a more complete patient profileand potentially increasing the effectiveness of personalized treatments. ACT Genomics aims to offer physicians a more holistic picture of theirpatients’ cancer. This integrated approach can better support therapyselection, predict drug resistance, and uncover new therapeutic targets,ensuring that patients receive the most effective, tailored treatment plans.

“This collaboration underscores the criticalrole proteomics plays in understanding how tumor biology evolves,”said Peter Chen, CEO of mProbe Inc.“ACT Genomics’ proven track record and extensivenetwork in Asia make them an ideal partner to accelerate the adoption ofOncoOmicsDX, ultimately improving patients care across the region.”

Through the combined expertise andresources, ACT Genomics and mProbe Inc. are committed to driving the future ofprecision oncology forward, championing research, clinical innovation, and theintegration of multi-omic data for better patient outcome scares. Interestedclinicians and researchers can learn more about OncoOmicsDX by contacting ACTGenomics directly.

About ACT Genomics

ACT Genomics is aleading precision medicine company specializing in genomic profiling andadvanced molecular diagnostics. Based in Taiwan with operations across Asia,the company provides cutting-edge genomics solutions that empower oncologiststo make informed treatment decisions and improve patient care. For moreinformation, please visit https://www.actgenomics.com/.

About mProbe

mProbe Inc. is a global precision diagnostics companyspecializing in proteomics. Through its advanced mass spectrometry and AI-basedplatforms, mProbe delivers actionable insights that enhance cancer treatmentstrategies and improve patient outcomes. For more information, please visit https://www.mprobe.com/.

‍